Lemtrada is Genzyme’s Second MS Treatment to Gain NHS Reimbursement Following Recent NICE Approval of Once-Daily, Oral Aubagio May 27, 2014 Genzyme, a Sanofi company, …
Slowing of Brain Atrophy and Reductions in New Multiple Sclerosis Lesions Sustained at Three Years in Patients Treated with Genzyme’s Lemtrada
Consistent effects seen across key MRI measures of disease activity; Effects were sustained beyond two-year pivotal MS studies Approximately 80 percent of patients treated …
Genzyme’s Lemtrada™ Approved in Brazil for Treatment of Multiple Sclerosis
March 21, 2014 Genzyme, a Sanofi company, announced today that Brazil’s national health surveillance agency, ANVISA, has approved Lemtrada (alemtuzumab) for the treatment of patients …